ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
0.00%
US Dollar vs MXN
17.5513
3.30%
Brent Oil
81.075
0.33%
Bitcoin
69,068.06
1.95%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) Noticias

RGLS Regulus Therapeutics Inc

2.29
0.00 (0.00%)
Pre Mercado
Última actualización: 06:35:03
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Regulus Therapeutics Inc RGLS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 2.29 06:35:03
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.29
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
21/5/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202415:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
17/5/202416:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:02EDGAR2Form 8-K - Current report
16/5/202407:00PRNUSRegulus Therapeutics Announces Promotion of Rekha Garg,..
09/5/202415:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/5/202415:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:15EDGAR2Form 8-K - Current report
09/5/202415:05PRNUSRegulus Therapeutics Reports First Quarter 2024 Financial..
06/5/202407:00PRNUSRegulus Therapeutics Advances to Cohort 4 of Phase 1b..
30/4/202407:00PRNUSRegulus Therapeutics to Participate in the Canaccord Genuity..
21/3/202415:05PRNUSRegulus Therapeutics Reports Fourth Quarter and Year-End..
12/3/202405:32PRNUSRegulus Therapeutics Announces Oversubscribed $100 Million..
12/3/202405:30PRNUSRegulus Therapeutics Announces Positive Topline Data from..
18/1/202419:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202419:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202415:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
02/1/202415:05PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
27/12/202315:16EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202307:00PRNUSRegulus Therapeutics to Present at the 6th Annual Evercore..
09/11/202315:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:15EDGAR2Form 8-K - Current report
09/11/202315:05PRNUSRegulus Therapeutics Reports Third Quarter 2023 Financial..
02/11/202307:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Third..
19/10/202307:00PRNUSRegulus Therapeutics Advances to Cohort 3 of Phase 1b..
20/9/202306:00PRNUSRegulus Therapeutics Announces Positive Topline Data from..
13/9/202307:00PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
05/9/202307:00PRNUSRegulus Therapeutics Announces Participation at Two..
23/8/202307:00PRNUSRegulus Therapeutics to Host Virtual Investor Event on..
14/8/202315:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202315:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:15EDGAR2Form 8-K - Current report
08/8/202315:05PRNUSRegulus Therapeutics Reports Second Quarter 2023 Financial..
02/8/202307:00PRNUSRegulus Therapeutics to Present at the Canaccord Genuity..

Su Consulta Reciente

NASDAQ
RGLS
Regulus Therapeutics
TG
T2V1
Tryg AS
LATK
MVCUSDT
Multiverse Capital (MVC.finance)
LSE
GAN
Gan
NYSE
FBHS
Fortune Brands Home and ...
COIN
NORMIEUST
Normie
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados